Maxim Group Starts Titan Medical (TMDI) at Buy

Maxim Group initiates coverage on Titan Medical (NASDAQ: TMDI) with a Buy rating and a price target of $11.00.

Analyst Anthony Vendetti highlighted:

• Titan is developing its SPORT Surgical System for use in single-incision robot-assisted surgery (RAS).
• According to Meddevicetracker, the global RAS market is $3B and growing at a CAGR of 11.7%.
• Titan's single-port system offers a less-invasive alternative to multi-port surgery for certain indications.
• Titan is targeting FDA and CE Mark clearance by mid-2020, with a controlled rollout commencing in 2H20

For an analyst ratings summary and ratings history on Titan Medical click here. For more ratings news on Titan Medical click here.

Shares of Titan Medical closed at $5.90 yesterday.

You May Also Be Interested In

• Loop Capital Starts Rubrik Inc (RBRK) at Buy
• JPMorgan Downgrades Sampo Oyj (SAMPO:FH) (SAXPY) to Neutral
• Berenberg Upgrades BE Semiconductor (BESI:NA) (BESIY) to Buy